Once-daily LIXIANA® (edoxaban) provides clear guidance to help you switch patients to and from other anticoagulants when necessary.1,2

In the ENGAGE AF-TIMI 48 Trial, a comprehensive switching plan to open-label anticoagulation therapy was implemented.

  • This resulted in a low and evenly distributed number of events after the discontinuation of study therapy (11 patients taking warfarin had an event that led to discontinuation vs 10 patients taking LIXIANA® (edoxaban)).2